Goldman says this newly public obesity play can surge nearly 60%

Goldman Sachs initiated coverage on newly public virtual care company Omada Health with a "buy" rating and a $29 price target, suggesting 58.5% potential upside. Analyst David Roman highlighted Omada's strong growth trajectory, near-term path to profitability, and below-peer valuation within the large and expanding chronic care market, citing the company's Q1 revenue jump of 57% to $55 million. Despite this bullish outlook and its virtual support model for conditions like diabetes, Omada's shares have slightly declined since their June 6 IPO at $19.

Analysis

Goldman Sachs has initiated coverage on newly public virtual care provider Omada Health (OMDA) with a "Buy" rating and a 12-month price target of $29, implying a significant 58.5% potential upside. The analyst's bullish thesis is anchored in the company's compelling risk/reward profile, which is supported by a strong growth trajectory, a visible path to near-term profitability, and a valuation below its peers. Omada's financial performance substantiates this view, with first-quarter revenue accelerating 57% year-over-year to $55 million, following a 38% increase in annual revenue to $169.8 million in the prior year. The company operates in a large and expanding market, targeting the over $1 trillion annual cost burden of chronic conditions in the U.S. through a "between-visit care model" that has demonstrated robust clinical evidence and a strong ROI proposition for payors. Future growth is expected to be catalyzed by strategic partnerships with EncircleRx and CVS, as well as its GLP-1 program. Despite this positive outlook, the stock has traded down slightly since its IPO at $19 per share in early June, presenting a potential disconnect between market sentiment and fundamental analysis.

Key Decisions for Investors

• Given the strong analyst endorsement, significant revenue growth of 57% in Q1, and the stock's slight decline post-IPO, long-term growth investors may view current levels as an attractive entry point.
• Investors should closely monitor the company's progress toward its stated goal of near-term profitability and the material impact of its strategic partnerships, including with CVS and the GLP-1 program, as these are cited as primary future revenue drivers.
• Potential investors must weigh the bullish fundamental case against the inherent volatility of a newly public company and consider the current post-IPO price weakness when timing a potential investment.